Stay updated with breaking news from Complete Remission. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in
House Majority Leader Steve Scalise (R-La.) is in “complete remission” after treatment for blood cancer and will return to Washington for votes next week after an extended absence, his office announced Thursday. “Leader Scalise has successfully completed his autologous stem cell treatment and has been medically cleared to resume travel,” Scalise’s office said in a…
NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual...
<p>A study led by researchers at <a href="https://umiamihealth.org/en/sylvester-comprehensive-cancer-center"><strong>Sylvester Comprehensive Cancer Center</strong></a> suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Video available.</p>
/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...